Concomitant or sequential administration of live attenuated Japanese encephalitis chimeric virus vaccine and yellow fever 17D vaccine

This publication has 20 references indexed in Scilit:

• Protection against Japanese encephalitis virus strains representing four genotypes by passive transfer of sera raised against ChimeriVax™-JE experimental vaccine
  Vaccine, 2004
• Chimeric Live, Attenuated Vaccine against Japanese Encephalitis (ChimeriVax‐JE): Phase 2 Clinical Trials for Safety and Immunogenicity, Effect of Vaccine Dose and Schedule, and Memory Response to Challenge with Inactivated Japanese Encephalitis Antigen
  The Journal of Infectious Diseases, 2003
• New initiatives for the control of Japanese encephalitis by vaccination:
  Vaccine, 2000
• Recombinant, chimaeric live, attenuated vaccine (ChimeriVax™) incorporating the envelope genes of Japanese encephalitis (SA14-14-2) virus and the capsid and nonstructural genes of yellow fever (17D) virus is safe, immunogenic and protective in non-human primates
  Vaccine, 1999
• Effectiveness of live-attenuated Japanese encephalitis vaccine (SA14-14-2): a case-control study
  The Lancet, 1996
• Japanese Encephalitis Vaccine: Persistence of Antibody up to 3 Years after a Three-Dose Primary Series
  The Journal of Infectious Diseases, 1995
• Homologous and heterologous neutralization antibody responses after immunization with Japanese encephalitis vaccine among Taiwan children
  Journal of Medical Virology, 1994
• Adverse reactions to Japanese encephalitis vaccine
  The Lancet, 1991
• Protection against Japanese Encephalitis by Inactivated Vaccines
  New England Journal of Medicine, 1988
• Japanese Encephalitis Vaccine
  Pediatrics International, 1988